New real-world data confirms efficacy and safety of Pepaxti
Oncopeptides today announced the publication of two real-world evidence (RWE) abstracts on Pepaxti at the International Myeloma Society (IMS) Annual Meeting in Toronto.
The Italian study reports a 47% overall response rate (ORR) in a heavily pretreated patient population, including patients previously treated with novel immunotherapies. The Spanish study confirms Pepaxti’s efficacy in an even more advanced patient group, providing highly relevant data for clinicians and payers. Both studies reaffirm Pepaxti’s favorable tolerability profile in real-world clinical practice.